BLOCK LISTING SIX MONTHLY RETURN
Date: 11 May 2022
| Name of applicant: | GlaxoSmithKline plc | |||
| Name of scheme: | GlaxoSmithKline plc 2017 Deferred Annual Bonus Plan | |||
| Period of return: | From: | 1 November 2021 | To: | 30 April 2022 |
| Balance of unallotted securities under scheme(s) from previous return: | 265,519 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 221,300 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 44,219 | |||
| Name of applicant: | GlaxoSmithKline plc | |||
| Name of scheme: | GlaxoSmithKline plc Share Save Plan 2012 | |||
| Period of return: | From: | 1 November 2021 | To: | 30 April 2022 |
| Balance of unallotted securities under scheme(s) from previous return: | 3,069,147 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 1,695,652 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 1,373,495 | |||
| Name of contact: | Victoria Whyte |
| Telephone number of contact: | 020 8047 5000 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
